Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Pharmaceutical 92

Pharmaceutical

MyoKardia & Eidos purchase; Amgen's Aimovig; HCV discovery; Bharat Biotech's Covaxin

Notizia - Recent Pharma, Healthcare and Biotech Happenings

MyoKardia buyout; Eidos acquisition; Amgen’s Aimovig; HCV discovery; Bharat Biotech’s Covaxin

MyoKardia Buyout: BMS expands its cardiovascular portfolio for USD 13.1 Billion Bristol Myers Squibb has bounty years in a go with its shares skyrocketing as it decides to go on an acquisition spree. BMS has announced to acquire MyoKardia, a pharmaceutical company leveraging precision medicine to treat cardiomyopathies and other forms of heart failure. BMS, according to the deal signed between the participating pharmaceuticals, will shell out USD 225 per share in cash in return of MyoKardia’s mavacamten, a novel, first-in-class, small molecule, allosteric inhibitor of cardiac-specific myosin adenosine triphosphatase under rigorous testing to...

Explore More...

Snippet

transthyretin amyloidosis

NOTIZIA

transthyretin amyloidosis

Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Achillion will leave this month; Lincoln’s anti-malarial drug

Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE) – Market Is Expected to Grow with Upcoming Therapies

transthyretin amyloidosis

Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allergan on women’s health

Gaucher Disease

Gaucher Disease: “Rare Disorder with High Unmet Needs”

Entasis

December 7 Business Cocktail

Notizia

KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s Repatha

Toll-Like Receptor Modulators: Emerging therapy for many indications

Ketamine to work in mice

BioGen

Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial

celiac disease

Celiac Disease (CD) – Upcoming therapies to break the stagnancy

Default Blog Image

Targeting cancer through CD40 agonists -A promising future

EMA to relocate to Amsterdam; Roche’s prospects; Amgen’s Humira Biosimilar delayed; Purdue’s opioid lawsuit

Chemists may help solve the air-pollution health crisis

Default Blog Image

Novartis ventures; Bill Gates invests; Arcus Biosciences gains; Denali and Odonate seek funding; Fosun Pharma acquires

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly